Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form
D-Scholarship @ Pitt Banner and Links to Homepage

PharmacoAnalytics: Assessing the Relationship Between Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Utilization and Dementia Incidence

Qi, Junnan (2024) PharmacoAnalytics: Assessing the Relationship Between Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Utilization and Dementia Incidence. Master's Thesis, University of Pittsburgh. (Unpublished)

This is the latest version of this item.

[img] PDF
Restricted to University of Pittsburgh users only until 25 April 2026.
Download (724kB) | Request a Copy

Abstract

Aims: To evaluate whether GLP-1 RAs, a newer generation of antidiabetic medication, will lower dementia risk compared to all other antidiabetic medications in the type 2 diabetes population.
Materials and Methods: All type 2 diabetes Mellitus (T2DM) patients who dispensed antidiabetic medications from June 2005 to December 2022 in the National Alzheimer’s Coordinating Center (NACC) database entered the study. A propensity score matching a ratio of 1 to 2 was used to balance baseline covariates. Kaplan-Meier analysis was applied to compare the probability of dementia incidents over time. A Multivariate Cox regression model was performed to obtain significant predictors, presenting adjusted hazard ratios (aHR) and Confidence Intervals (CIs) for the time to dementia incidence.
Results: After 1 to 2 propensity score matching, the final cohort consisted of 133 GLP-1 RA users and 266 non-users. Kaplan-Meier demonstrated that GLP-1 users were associated with a lower risk of developing dementia compared to non-users (p=0.0123). The Multivariate Cox regression model identifies GLP-1 RA (aHR 0.42, 95%Confidence Interval (CI): [0.22-0.80], p=0.009) and female (aHR: 0.50, 95%CI: [0.29-0.87], p=0.01) as protective factors for dementia, while age ( aHR: 1.07, 95%CI: [1.03-1 .10], p=0.01), 2 pairs of APOE4 genes (aHR: 2.42, 95%CI: [1.43-4.09], p=0.001), and depression (aHR: 3.30, 95%CI: [1.87-5.84], p<0 .0001) were associated with a higher risk of dementia.
Conclusion: GLP-1 RAs were associated with a lower risk of dementia incidence in the T2DM population. Further studies are warranted.
Keywords: dementia, type 2 diabetes mellitus, glucagon-like peptide-1 receptor agonist, antidiabetic medication, NACC

Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: University of Pittsburgh ETD
Status: Unpublished
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Qi, Junnanjuq9@pitt.edujuq90009-0009-3735-2425
ETD Committee:
TitleMemberEmail AddressPitt UsernameORCID
Committee ChairFeng, Zhiweizhf11@pitt.edu
Committee CoChairXue, Yingyix49@pitt.edu
Committee MemberXiang-Qun, Xiexix15@pitt.edu
Thesis AdvisorXue, Yingyix49@pitt.edu
Date: 25 April 2024
Date Type: Publication
Defense Date: 28 March 2024
Approval Date: 25 April 2024
Submission Date: 16 April 2024
Access Restriction: 2 year -- Restrict access to University of Pittsburgh for a period of 2 years.
Number of Pages: 63
Institution: University of Pittsburgh
Schools and Programs: School of Pharmacy > Pharmaceutical Sciences
Degree: MS - Master of Science
Thesis Type: Master's Thesis
Refereed: Yes
Uncontrolled Keywords: dementia, type 2 diabetes mellitus, glucagon-like peptide-1 receptor agonist, antidiabetic medication, NACC
Date Deposited: 25 Apr 2024 15:45
Last Modified: 25 Apr 2024 15:45
URI: http://d-scholarship.pitt.edu/id/eprint/46134

Available Versions of this Item

  • PharmacoAnalytics: Assessing the Relationship Between Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Utilization and Dementia Incidence. (deposited 25 Apr 2024 15:45) [Currently Displayed]

Metrics

Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item